Fourteen weeks of liraglutide therapy in subjects with type 2 diabetes significantly improves first phase insulin secretion and maximal beta-cell secretory capacity

被引：0
作者：
Madsbad, S.
Brock, B.
Perrild, H.
Lervang, H. H.
Kolendorf, K.
Krarup, T.
Schmitz, O.
Le-Thi, T.
Zdravkovic, M.
Vilsboll, T.
机构：
[1] Hvidovre Univ Hosp, DK-2650 Hvidovre, Denmark
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Bispebjerg Univ Hosp, Copenhagen, Denmark
[4] Aarhus Univ Hosp, Aalborg, Denmark
[5] Roskilde Cty Psychiat Hosp Fjorden, Roskilde, Denmark
[6] Gentofte Univ Hosp, Hellerup, Denmark
[7] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0004
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [1] The GLP-1 analogue liraglutide improves first-phase insulin secretion and maximal beta-cell secretory capacity over 14 weeks of therapy in subjects with Type 2 diabetes
    Madsbad, S.
    Vilsboell, T.
    Brock, B.
    Perrild, H.
    Lervang, H-H
    Kolendorf, K.
    Krarup, T.
    Schmitz, O.
    Zdravkovic, M.
    Le-Thi, T.
    DIABETIC MEDICINE, 2007, 24 : 4 - 4
  • [2] Impaired beta-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes
    Elder, Deborah A.
    Woo, Jessica G.
    Dolan, Lawrence M.
    D'alessio, David A.
    DIABETES, 2008, 57 : A67 - A67
  • [3] Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
    Matthews, D. R.
    Marre, M.
    Le-Thi, T. D.
    Zdravkovic, M.
    Simo, R.
    Garber, A.
    Zinman, B.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [4] Imeglimin Increases Glucose-dependent Insulin Secretion and Improves Beta-Cell Function in Patients with Type 2 Diabetes
    Pacini, Giovanni
    Mari, Andrea
    Brazzale, Alessandra R.
    Fouqueray, Pascale
    Bolze, Sebastien
    Roden, Michael
    DIABETES, 2014, 63 : A32 - A32
  • [5] Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
    Rosenstock, Julio
    Robins, Deborah A.
    Duffin, Kevin L.
    Wilson, Jonathan M.
    Mather, Kieren J.
    Banerjee, Hiya
    Lin, Yanzhu
    Eyde, Sarah
    Kazda, Christof M.
    Konig, Manige
    DIABETES, 2024, 73
  • [6] Impaired β-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes
    Elder, Deborah A.
    Woo, Jessica G.
    D'Alessio, David A.
    PEDIATRIC DIABETES, 2010, 11 (05) : 314 - 321
  • [7] A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes
    Ribbing, Jakob
    Hamren, Bengt
    Svensson, Maria K.
    Karlsson, Mats O.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (08) : 861 - 872
  • [8] TRAINING AND BETA-CELL SECRETION IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES
    VONLINSTOW, M
    DELA, F
    MIKINES, KJ
    GALL, M
    GALBO, H
    DIABETOLOGIA, 1992, 35 : A109 - A109
  • [9] Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function
    Mayfield, JA
    White, RD
    AMERICAN FAMILY PHYSICIAN, 2004, 70 (03) : 489 - 500
  • [10] Alogliptin Improves Model-assessed Beta-Cell Function in 52 Weeks in Type 2 Diabetes Patients
    Okahata, Sumie
    Sakamoto, Kentaro
    Shiba, Teruo
    DIABETES, 2015, 64 : A652 - A652
12345